– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals pursuant to the asset purchase agreement dated ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS), Monday announced the completion of its previously announced divestiture of the UDENYCA or pegfilgrastim-cbqv franchise to Intas Pharmaceuticals Ltd ...